Progressive Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Progressive Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-11Clinical Trial Update: A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis [Phase 2, Phase 3]
A clinical trial update for NeuroVax, a therapeutic TCR peptide vaccine being studied in secondary progressive and general multiple sclerosi…
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: A Study of Oxidative Pathways in MS Fatigue [Phase 2]
This Phase 2 clinical trial evaluated oxidative pathways related to fatigue in progressive multiple sclerosis, with results posted in Februa…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Autologous Mesenchymal Stromal Cells for Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 trial assessing autologous mesenchymal stromal cells in relapsing-remitting and secondary progressive multiple sclerosis has compl…
-
FDA approval · 2020-01-10FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for OCREVUS (ocrelizumab) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition [Phase 2]
Phase 2 trial evaluating estriol treatment for cognitive effects in multiple sclerosis patients.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis [NA]
An open-label study evaluating the efficacy of ECP in secondary progressive multiple sclerosis has terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients [Phase 2, Phase 3]
A completed Phase 2/3 trial comparing rituximab to glatiramer acetate in secondary progressive multiple sclerosis.
-
FDA approval · 2019-03-26FDA Approved: MAYZENT — Original Application (Novartis Pharmaceuticals Corporation)
FDA approves Mayzent (siponimod) from Novartis Pharmaceuticals Corporation in an original NDA for the treatment of relapsing forms of multip…
-
CLINICAL_TRIALS trial_result · 2019-03-07Clinical Trial Update: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) [Phase 1, Phase 2]
Phase 1/2 clinical trial of idebenone for primary progressive multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-02-20Clinical Trial Update: Mitochondrial Dysfunction and Disease Progression
A completed clinical trial (NCT02549703) examining the role of mitochondrial dysfunction in disease progression across multiple sclerosis fo…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo [Phase 2]
Phase 2 trial evaluating two doses of laquinimod (0.6 mg/day and 1.5 mg/day) versus placebo for primary progressive multiple sclerosis; stud…
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) [Phase 3]
This update reports results from the Phase 3 EXPAND trial evaluating siponimod for secondary progressive multiple sclerosis, including asses…
-
CLINICAL_TRIALS research · 2018-06-27Clinical Trial Update: Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) [Phase 2]
Phase 2 trial update for ACTiMuS bone marrow-derived cellular therapy in progressive multiple sclerosis. The current status is unknown.
-
CLINICAL_TRIALS trial_result · 2018-06-11Clinical Trial Update: Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
This document provides an update on a clinical trial evaluating the incidence of relapses in patients with progressive multiple sclerosis tr…
-
CLINICAL_TRIALS research · 2018-03-22Clinical Trial Update: Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients [Phase 4]
Phase 4 clinical trial update examining indirect neuroprotective effects of Tecfidera (dimethyl fumarate) in relapsing-remitting and progres…
-
CLINICAL_TRIALS trial_result · 2017-12-26Clinical Trial Update: A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis [Phase 3]
Phase 3 trial update for ocrelizumab in primary progressive multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-10-25Clinical Trial Update: The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis. [NA]
This completed clinical trial evaluated the impact of high-intensity interval training on cardiovascular fitness in people with progressive …
-
CLINICAL_TRIALS trial_result · 2017-08-30Clinical Trial Update: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients [Phase 1]
This update reports the completion of a Phase 1 trial evaluating intrathecal rituximab in patients with progressive multiple sclerosis (prim…
-
CLINICAL_TRIALS trial_result · 2017-07-14Clinical Trial Update: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis [Phase 2]
Phase 2 safety and efficacy results for MIS416 in secondary progressive multiple sclerosis have been reported. The study was sponsored by In…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS) [NA]
This update reports the completion of a clinical trial focused on treating learning and memory deficits in progressive multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-06-27Clinical Trial Update: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis [Phase 3]
Phase 3 clinical trial evaluating natalizumab for reducing disability progression in secondary progressive multiple sclerosis; study termina…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. [Phase 3]
Open-label extension of a double-blind, randomized Phase 3 core study in primary progressive multiple sclerosis; the trial was terminated an…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis [Phase 3]
Phase 3 trial evaluating oral prolonged-release dalfampridine (BIIB041) for safety and efficacy in Japanese participants with multiple scler…
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis [Phase 1, Phase 2]
An update on a dose-escalation Phase 1/2 trial of Opexa's autologous T cell vaccine for relapsing-remitting and secondary progressive multip…
-
CLINICAL_TRIALS trial_result · 2017-01-10Clinical Trial Update: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis [Phase 2]
This update reports the Phase 2 clinical trial of Imilecleucel-T (Tcelna) for secondary progressive multiple sclerosis, which has completed …